Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 6,000 shares of the stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the sale, the insider now owns 6,000 shares of the company’s stock, valued at approximately $479,700. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Daniel Faga also recently made the following trade(s):

  • On Tuesday, October 24th, Daniel Faga sold 7,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $80.96, for a total value of $607,200.00.
  • On Tuesday, September 19th, Daniel Faga sold 1,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.00, for a total value of $127,500.00.
  • On Tuesday, September 12th, Daniel Faga sold 6,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $82.50, for a total value of $495,000.00.
  • On Thursday, September 7th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.02, for a total value of $255,060.00.

Shares of Spark Therapeutics, Inc. (ONCE) traded up 2.15% on Tuesday, reaching $85.49. 728,429 shares of the company were exchanged. The stock has a 50 day moving average of $85.27 and a 200-day moving average of $85.27. The company’s market capitalization is $2.67 billion. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. During the same quarter in the previous year, the company posted ($1.04) earnings per share. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. On average, analysts predict that Spark Therapeutics, Inc. will post ($7.59) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/24/spark-therapeutics-inc-once-insider-daniel-faga-sells-6000-shares.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its position in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Spark Therapeutics during the second quarter worth about $143,000. BNP Paribas Arbitrage SA grew its position in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Pacad Investment Ltd. grew its position in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in Spark Therapeutics during the first quarter worth about $227,000. Institutional investors own 77.29% of the company’s stock.

Several research firms recently issued reports on ONCE. SunTrust Banks, Inc. set a $101.00 target price on Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, October 16th. Barclays PLC upped their target price on Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a research report on Friday, October 13th. Cantor Fitzgerald cut their target price on Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating on the stock in a research report on Friday, October 13th. Stifel Nicolaus reissued a “buy” rating and issued a $101.00 target price (up from $92.00) on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $101.00 target price (up from $89.00) on shares of Spark Therapeutics in a research report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $90.47.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.